Nebraska Medicaid DUR Board Meeting Tuesday, November 6, 2018 DRAFT pending approval at January Meeting

DUR Board Members in Attendance:

Kevin Borcher, RP Lynn Carlson, RP Shana Castillo, RP Norman Kelley, MD Madeline Leiter, CU PharmD Candidate Roger Mattson, RP Charlie Moore, RP Marcia Mueting, RP Kirk Muffly, MD David Randolph, RP Phil Vuchetich, RP Robert Wergin, MD

DUR Board members not in Attendance:

Nichole Boggs, UNMC PharmD Candidate Eric Gall, RP Bruce Houghton, MD Susan Howard, MD

Guests in Attendance:

Jill Bot, RP Magellan Medicaid Administration Valarie Simmons, Magellan Medicaid Administration Ashleigh Grammar UNMC PharmD Candidate Jenny Minchow, RP Nebraska Medicaid & LTC Services Shannon Nelson, RP, WellCare of Nebraska (WC) Kevin Peterson, RP, Nebraska Total Care (NTC) Bernadette Ueda, RP, United Health Care (UHC)

Public Members in Attendance:

Melissa Basil, Abbvie Mike Donze, Genentech Garth Wright, Genentech Dawn Bina, Novonordisk Edie Dodson, Sanofi Genzyme Derek Classen, UNMC PharmD Candidate Tanner Griffith, UNMC PharmD Candidate Zach Kaster, UNMC PharmD Candidate

I. Opening and Introductions

The meeting was called to order at 6:30 p.m. by DUR Director, Marcia Mueting. The Director noted that a copy of the Open Meeting Laws and the meeting materials were available. Public attendees were asked to complete the sign-in sheet if they wished to be listed in the minutes as attending. Board members, guests and public attendees introduced themselves.

II. Declaration of Any Conflict of Interest Changes

No changes were declared.

III. Approval of the Agenda

A motion was made by Charlie Moore with a second from Phil Vuchetich to approve the agenda as presented. Vote as follows: Borcher-yes, Carlson-yes, Castillo-yes, Kelley-yes, Mattson-yes, Moore-yes, Muffly-yes, Randolph-yes, Vuchetich-yes and Wergin-yes. Motion carried.

IV. Approval of Minutes from September Meeting

A motion was made by Norman Kelley with a second from David Randolph to approve the minutes as presented. Vote as follows: Borcher-yes, Carlson-yes, Castillo-yes, Kelley-yes, Mattson-yes, Moore-yes, Muffly-yes, Randolph-yes, Vuchetich-yes and Wergin-yes. Motion carried.

V. Update on Recommendations from September Meeting

No discussion.

VI. Retrospective DUR

A. Current Profile Review

1. Restricted Services (RS)

Marcia Mueting reported that in Fee-For-Service (FFS) the criteria for restricted services review is patients utilizing 6 or more prescribers and 3 or more pharmacies in a month. No patients met the criteria in September or October.

Shannon Nelson with WC shared that in September there were 24 members who met the criteria for review. 8 were referred to case management. 4 were added to RS. 4 had no further follow up. 2 members were released from RS upon biennial review. In October, 23 members were reviewed. 13 were referred to case management. 1 was added to RS. 8 required no action.

Kevin Peterson with NTC shared that in September, 25 members were reviewed. 1 member was added to RS. 5 members were removed from RS after biennial review. In October, 18 members met the criteria for review. 1 was added to RS. 4 were removed from RS upon biennial review.

Bernadette Ueda of UHC explained that in September 6 members were reviewed. 4 were added to RS. 2 were removed from RS upon biennial review. There is a total of 133 members in RS, all of whom are in case management. There was not a meeting in October for review of patients utilizing multiple providers.

2. MME Daily Limit of 300 Implementation Date: December 6, 2018

Bernadette Ueda explained that letters were recently sent on these patients. No additional information is available.

3. 7 Day Limit in Opioid-Naïve Patients (max of 50 MME per day) Bernadette Ueda reported that 1,093 letters were sent to prescribers. To date, 150 responses were received. 44 found the information useful. 67 said that the information was not useful. 48 prescribers noted that they planned to change the therapy, and 11 prescribers indicated that they would monitor the patient.

4. Adult patients taking stimulants exceeding the FDA-Approved Limits Bernadette Ueda shared that 398 letters were sent. Only 2 responses have been received to date. 1 indicated that the information was useful, the other indicated that the information was not useful.

5. Concomitant Antipsychotics in Children

Shannon Nelson of WC reported that 168 letters were sent on June 27th. 10 responses were received.

Kevin Peterson explained that NTC has an ongoing project to monitor this issue. On average, the PUMR team sends 3 letters per week to prescribers on mental health drug utilization.

Bernadette Ueda noted that UHC did not send letters on this topic.

6. Concomitant Mood Stabilizers

Marcia Mueting explained that the DUR Program will be sending letters moving forward on projects recommended by the DUR Board and will be working with the plans to get information for the letters.

B. Recommendations for Future Profile Reviews

Letters will be sent in November on concomitant antidepressants medications in children. Letters will be sent in December on patients exceeding 250 MME. Board discussion resulted in a consensus to provide prescribers the morphine equivalent chart to calculate a patient's MME with those letters.

VII. Prospective DUR

A. New Business

1. New Drug Review – Jynarque

There was no public comment. Shana Castillo made a motion to recommend prior authorization on Jynarque with the criteria as drafted with a second from Phil Vuchetich. Vote as follows: Borcher-yes, Carlson-yes, Castillo-yes, Kelley-yes, Mattson-yes, Moore-yes, Muffly-yes, Randolph-yes, Vuchetich-yes and Wergin-yes. Motion carried.

2. Annual Review of Growth Hormone Prior Authorization Criteria

There was no public comment. Lynn Carlson made a motion to recommend approval of the criteria as presented with a second from Bob Wergin. Vote as follows: Borcher-yes, Carlson-yes, Castillo-yes, Kelley-yes, Mattson-yes, Moore-yes, Muffly-yes, Randolph-yes, Vuchetich-yes and Wergin-yes. Motion carried.

3. Annual Review of IGF-1 Prior Authorization

There was no public comment. Norman Kelley made a motion to recommend approval of the criteria as presented with a second from Dave Randolph. Vote as follows: Borcher-yes, Carlson-yes, Castillo-yes, Kelley-yes, Mattson-yes, Moore-yes, Muffly-yes, Randolph-yes, Vuchetich-yes and Wergin-yes. Motion carried.

Old Business

1. Review Draft Criteria for Prior Authorization of Long-Acting Opioids

Board members reviewed the number of patients who were considered opioid naïve (no claims for an opioid in 90 previous days) that received a long-acting opioid. There was no public comment. There were approximately 350 patients who met the criteria. A motion was made to recommend a prior authorization for the use of longacting opioids in opioid naïve patients by Dave Randolph with a second from Bob Wergin. Vote as follows: Borcher-no, Carlson-yes, Castillo-yes, Mattson-yes, Mooreyes, Muffly-yes, Randolph-yes, Vuchetich-yes and Wergin-yes. Motion carried. Board discussion resulted in a consensus that when letters are sent to prescribers of patients exceeding 90 MME per day that a recommendation for a naloxone prescription be provided by the prescribers.

VIII. Special Requests from the Department None.

IX. Future Meeting Dates

January 8, 2019 March 12, 2019 May 14, 2019 July 9, 2019 September 10, 2019 November 12, 2019

X. Concerns and Comments from

Board – A Board Member asked about the impact of the ballot initiative to expand Medicaid in Nebraska. There was discussion of rolling patients into existing plans, but more information will be available after the results of the election. Director – None. State Representatives- None. Managed Care Organization Representatives- None. Public Attendees- None.

XI. Adjournment

A motion was made by Charlie Moore with a second from Phil Vuchetich to adjourn at 7:43 p.m. Vote as follows: Borcher-yes, Carlson-yes, Castillo-yes, Kelley-yes, Mattson-yes, Moore-yes, Muffly-yes, Randolph-yes, Vuchetich-yes and Wergin-yes. Motion carried.